<?xml version="1.0" encoding="UTF-8" standalone="no"?><rdf:RDF xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#" xmlns="http://purl.org/rss/1.0/" xmlns:admin="http://webns.net/mvcb/" xmlns:content="http://purl.org/rss/1.0/modules/content/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:prism="http://purl.org/rss/1.0/modules/prism/" xmlns:syn="http://purl.org/rss/1.0/modules/syndication/" xmlns:taxo="http://purl.org/rss/1.0/modules/taxonomy/">

<channel rdf:about="http://www.bmj.com">
<title>Latest headlines from BMJ</title>
<link>http://www.bmj.com</link>
<description></description>
<prism:eIssn>1756-1833</prism:eIssn>
<prism:publicationName>BMJ</prism:publicationName>
<items>
 <rdf:Seq>
  <rdf:li rdf:resource="http://www.bmj.com/content/394/bmj-2026-100354.short?rss=1"/>
  <rdf:li rdf:resource="http://www.bmj.com/content/394/bmj-2026-100362.short?rss=1"/>
  <rdf:li rdf:resource="http://www.bmj.com/content/394/bmj-2026-100119.short?rss=1"/>
  <rdf:li rdf:resource="http://www.bmj.com/content/394/bmj-2026-100373.short?rss=1"/>
  <rdf:li rdf:resource="http://www.bmj.com/content/394/bmj-2026-100266.short?rss=1"/>
  <rdf:li rdf:resource="http://www.bmj.com/content/394/bmj-2026-100378.short?rss=1"/>
 </rdf:Seq>
</items>
<image rdf:resource="http://www.bmj.com/icons/site/logo.bmj.gif"/>
<xhtml:meta content="noindex" name="robots" xmlns:xhtml="http://www.w3.org/1999/xhtml"/></channel>
<image rdf:about="http://www.bmj.com/icons/site/logo.bmj.gif">
<title>BMJ</title>
<url>http://www.bmj.com/icons/site/logo.bmj.gif</url>
<link>http://www.bmj.com</link>
</image>
<item rdf:about="http://www.bmj.com/content/394/bmj-2026-100354.short?rss=1">
<title><![CDATA[Mandatory, standardised food labelling should be just one element of a multifaceted campaign against obesity]]></title>
<link>http://www.bmj.com/content/394/bmj-2026-100354.short?rss=1</link>
<description><![CDATA[We agree with Vogel that there is an abundance of unhealthy foods in many settings and that obesogenic environments are contributing to the obesity epidemic.1 The Institute of Health Promotion and Education and others have repeatedly called for a clear and consistent approach to food labelling to help increase awareness about the options on offer.234The UK has considerable variations in environment, and certain population groups are more at risk of becoming obese. There is strong evidence, for example, of increased incidence of obesity in families living in areas of deprivation.5 Even if we did have accurate and easy to read information on all foods, there are certain groups that may have limited choices.6Obesity is a complex issue that requires a range of coordinated actions, including providing healthy options in schools, hospitals, and other settings; limiting the clustering of fast food outlets; fiscal measures; tackling advertising and misinformation; provision of effective...]]></description>
<dc:creator><![CDATA[Michael Craig Watson, Karen E Neil]]></dc:creator>
<dc:date>2026-07-23T05:56:06-07:00</dc:date>
<dc:identifier>info:doi/10.1136/bmj-2026-100354</dc:identifier>
<dc:identifier>hwp:master-id:bmj;bmj-2026-100354</dc:identifier>
<dc:publisher>BMJ Publishing Group Ltd</dc:publisher>
<dc:title><![CDATA[Mandatory, standardised food labelling should be just one element of a multifaceted campaign against obesity]]></dc:title>
<prism:publicationDate>2026-07-23</prism:publicationDate>
<prism:section>Letters</prism:section>
<prism:subsection1>Letter</prism:subsection1>
<prism:volume>394</prism:volume>
<prism:issueIdentifier>jul23_10</prism:issueIdentifier>
</item>
<item rdf:about="http://www.bmj.com/content/394/bmj-2026-100362.short?rss=1">
<title><![CDATA[Why Burnham must take &#x201C;health first&#x201D; mainstream]]></title>
<link>http://www.bmj.com/content/394/bmj-2026-100362.short?rss=1</link>
<description><![CDATA[A new report by the Health Foundation estimates that restoring population health to the level of 2014 would not only improve people’s health and wellbeing but also produce an economic benefit of £72bn (doi:10.1136/bmj-2026-100335).1 In summary, the calculation is built on one fact and one assumption. The fact is that population health has deteriorated since 2014: the UK now has 15.7 million working age adults with a long term health condition, up from 11.7 million in 2014. The assumption is that reducing the number of working age adults with long term conditions unlocks economic benefits through improved economic output, additional tax revenues, and reduced welfare spending. This is only the latest in a long line of credible reports to demonstrate the economic upside of investing in health. The UK’s new prime minister, Andy Burnham, should take note.There’s no reason to think that the level of long term health conditions in...]]></description>
<dc:creator><![CDATA[Kamran Abbasi]]></dc:creator>
<dc:date>2026-07-23T05:21:24-07:00</dc:date>
<dc:identifier>info:doi/10.1136/bmj-2026-100362</dc:identifier>
<dc:identifier>hwp:master-id:bmj;bmj-2026-100362</dc:identifier>
<dc:publisher>BMJ Publishing Group Ltd</dc:publisher>
<dc:title><![CDATA[Why Burnham must take &#x201C;health first&#x201D; mainstream]]></dc:title>
<prism:publicationDate>2026-07-23</prism:publicationDate>
<prism:section>Editor's Choice</prism:section>
<prism:volume>394</prism:volume>
<prism:issueIdentifier>jul23_9</prism:issueIdentifier>
</item>
<item rdf:about="http://www.bmj.com/content/394/bmj-2026-100119.short?rss=1">
<title><![CDATA[Minimal detectable change of the Patient Health Questionnaire-9, Patient Health Questionnaire-8, and Patient Health Questionnaire-2: individual patient data meta-analysis]]></title>
<link>http://www.bmj.com/content/394/bmj-2026-100119.short?rss=1</link>
<description><![CDATA[AbstractObjectiveTo estimate the minimal detectable change (MDC) for the Patient Health Questionnaire-9 (PHQ-9) and its eight item (PHQ-8) and two item (PHQ-2) versions including differences by participant and study characteristics.DesignIndividual participant data meta-analysis.Data sourcesMedline, Medline In-Process and other non-indexed citations, PsycInfo, and Web of Science, 1 January 2000 to 9 May 2018.Eligibility criteria for selecting studiesDatasets from articles in any language if participants were aged ≥18 years, were recruited from any non-psychiatric setting, and were not recruited because they were seeking mental healthcare. Eligible datasets had a classification for major depressive disorder or major depressive episode based on a validated semi-structured or fully structured interview conducted within two weeks of administering the PHQ-9, PHQ-8, or PHQ-2.ResultsPooled MDCs across studies were estimated for the PHQ-9, PHQ-8, and PHQ-2 with random effects meta-analysis for 95% (MDC95), 90% (MDC90), and 67% (MDC67) confidence that change beyond measurement error occurred. PHQ-9, PHQ-8, and PHQ-2 analyses included 42 548 participants (94 studies), 42 592 participants (94 studies), and 44 085 participants (98 studies), respectively. Mean participant age was 49 years (standard deviation 17), and 60% of participants were women. Overall, 10% of participants had major depression (range 1-57% across studies). MDC95 was 5.72 points (95% confidence interval (CI) 5.54 to 5.90, 95% prediction interval (PI) 4.00 to 7.44) for the PHQ-9, 5.51 points (95% CI 5.33 to 5.68, 95% PI 3.87 to 7.15) for the PHQ-8, and 2.26 points (95% CI 2.15 to 2.37, 95% PI 1.20 to 3.32) for the PHQ-2. For the PHQ-9, MDC95 was highest in inpatient healthcare settings at 6.48 (95% CI 6.05 to 6.92) points. MDC95 for the PHQ-9 increased by 0.40 (95% CI 0.25 to 0.55) points for each 10% increase in the proportion of participants with major depression. Sex and age had minimal or no association. Subgroup and meta-regression findings were similar for the PHQ-8 and PHQ-2.ConclusionsBased on the pooled estimate, a six point difference on the PHQ-9, the PHQ version most used in clinical practice, could be an appropriate MDC threshold in general practice. A higher threshold may be preferred in specialty mental healthcare. MDC67 or MDC90 thresholds would provide less certainty that change has occurred. Alternative strategies, such as using the upper end of a prediction interval, would provide more certainty but a greater likelihood of not recognising change.Study registrationPROSPERO CRD42014010673.]]></description>
<dc:creator><![CDATA[Yutong Wang, Yin Wu, Nadia P Gonzalez&ndash;Dominguez, Jill T Boruff, Brooke Levis, Pim Cui&#x0237;pers, Simon Gilbody, Daphna Harel, John P A Ioannidis, Sarah Markham, Scott B Patten, Simone N Vigod, Roy C Ziegelstein, Andrea Benedetti, Brett D Thombs,  On behalf of the DEPRESsion Screening Data (DEPRESSD) PHQ Collaboration]]></dc:creator>
<dc:date>2026-07-23T05:11:20-07:00</dc:date>
<dc:identifier>info:doi/10.1136/bmj-2026-100119</dc:identifier>
<dc:identifier>hwp:master-id:bmj;bmj-2026-100119</dc:identifier>
<dc:publisher>BMJ Publishing Group Ltd</dc:publisher>
<dc:title><![CDATA[Minimal detectable change of the Patient Health Questionnaire-9, Patient Health Questionnaire-8, and Patient Health Questionnaire-2: individual patient data meta-analysis]]></dc:title>
<prism:publicationDate>2026-07-23</prism:publicationDate>
<prism:section>Research</prism:section>
<prism:volume>394</prism:volume>
<prism:issueIdentifier>jul23_8</prism:issueIdentifier>
</item>
<item rdf:about="http://www.bmj.com/content/394/bmj-2026-100373.short?rss=1">
<title><![CDATA[AI is expanding online sexual abuse against women and girls]]></title>
<link>http://www.bmj.com/content/394/bmj-2026-100373.short?rss=1</link>
<description><![CDATA[Growing awareness of online misogyny has converged with an explosion of AI driven digital violence against women. Over 11 days between December 2025 and January 2026, the AI tool Grok, developed by X, is estimated to have generated some three million sexualised images of women and girls, including more than 23 000 depicting children. At its peak, Grok was producing around one sexualised image of a child every 41 seconds.1 This marks a deeply worrying new phase of digital violence against women and children, in which abusive images can be generated by almost anyone and shared rapidly and widely. AI has expanded what was previously an episodic form of sexual abuse into mass, industrialised victimisation, with serious implications for public health.Image based sexual abuse is still widely described as “revenge porn,” but this term is misleading as it assumes a relationship, a retaliatory motive, and prior consensual participation in creating...]]></description>
<dc:creator><![CDATA[Stephanie Fohring]]></dc:creator>
<dc:date>2026-07-23T04:42:12-07:00</dc:date>
<dc:identifier>info:doi/10.1136/bmj-2026-100373</dc:identifier>
<dc:identifier>hwp:master-id:bmj;bmj-2026-100373</dc:identifier>
<dc:publisher>BMJ Publishing Group Ltd</dc:publisher>
<dc:title><![CDATA[AI is expanding online sexual abuse against women and girls]]></dc:title>
<prism:publicationDate>2026-07-23</prism:publicationDate>
<prism:section>Opinion</prism:section>
<prism:volume>394</prism:volume>
<prism:issueIdentifier>jul23_7</prism:issueIdentifier>
</item>
<item rdf:about="http://www.bmj.com/content/394/bmj-2026-100266.short?rss=1">
<title><![CDATA[Long term benefits of blood pressure lowering . . . and other research]]></title>
<link>http://www.bmj.com/content/394/bmj-2026-100266.short?rss=1</link>
<description><![CDATA[Polypills and heart failureCritics argue that limited dosing options for polypills mean patients get suboptimal care, whereas polypill advocates counter that polypills are a more feasible option: most patients—especially those with socio-economic barriers to care—don’t get close to receiving guideline directed therapy. An open label trial compared a polypill containing metoprolol succinate (dosing options: 25/50/100/150 mg), spironolactone 12.5 mg and empagliflozin 10 mg with enhanced usual care in people with symptomatic heart failure with a left ventricular ejection fraction (LVEF) <40%. The study population, from two centres in the United States, were mostly uninsured, and had high levels of unemployment and food insecurity. After six months, those in the polypill group showed better adherence to medication, higher LVEF, and lower rates of emergency department visit or hospitalisation for heart failure.Nat Med doi:10.1038/s41591-026-04504-5Can’t weight to sleepDragon’s Den star and podcast king Steven Bartlett caused outcry by saying that drinking three glasses...]]></description>
<dc:creator><![CDATA[Tom Nolan]]></dc:creator>
<dc:date>2026-07-23T03:51:16-07:00</dc:date>
<dc:identifier>info:doi/10.1136/bmj-2026-100266</dc:identifier>
<dc:identifier>hwp:master-id:bmj;bmj-2026-100266</dc:identifier>
<dc:publisher>BMJ Publishing Group Ltd</dc:publisher>
<dc:title><![CDATA[Long term benefits of blood pressure lowering . . . and other research]]></dc:title>
<prism:publicationDate>2026-07-23</prism:publicationDate>
<prism:section>Opinion</prism:section>
<prism:volume>394</prism:volume>
<prism:issueIdentifier>jul23_6</prism:issueIdentifier>
</item>
<item rdf:about="http://www.bmj.com/content/394/bmj-2026-100378.short?rss=1">
<title><![CDATA[Asthma: UK approves &#x201C;climate friendly&#x201D; low carbon inhalers]]></title>
<link>http://www.bmj.com/content/394/bmj-2026-100378.short?rss=1</link>
<description><![CDATA[Two new pressurised metered dose inhalers (pMDIs) with lower carbon emissions have been approved by the UK’s drug regulator in a world first.1The inhalers aim to reduce the devices’ environmental impact without affecting the treatment.Such pMDIs are the most commonly used inhalers in the UK, accounting for around 70% of the 60 million devices prescribed each year. But they also account for around 3% of the NHS’ greenhouse gas emissions—the largest single contributor of all medications.The Medicines and Healthcare Products Regulatory Agency (MHRA) has approved new versions of drug company Chiesi’s Clenil Modulite 100 μg inhaler and Clenil Modulite 200 μg inhaler.The updated versions still include beclometasone dipropionate but use a new propellant, HFA-152a, to deliver the inhaled dose rather than the previously used HFC-134a.Chiesi said the new propellant could cut the carbon footprint of these beclometasone products “by up to 90% versus that of the current propellant.”The new inhalers...]]></description>
<dc:creator><![CDATA[Elisabeth Mahase]]></dc:creator>
<dc:date>2026-07-23T03:31:14-07:00</dc:date>
<dc:identifier>info:doi/10.1136/bmj-2026-100378</dc:identifier>
<dc:identifier>hwp:master-id:bmj;bmj-2026-100378</dc:identifier>
<dc:publisher>BMJ Publishing Group Ltd</dc:publisher>
<dc:subject><![CDATA[Respiratory medicine]]></dc:subject>
<dc:title><![CDATA[Asthma: UK approves &#x201C;climate friendly&#x201D; low carbon inhalers]]></dc:title>
<prism:publicationDate>2026-07-23</prism:publicationDate>
<prism:section>News</prism:section>
<prism:volume>394</prism:volume>
<prism:issueIdentifier>jul23_5</prism:issueIdentifier>
</item>
</rdf:RDF>